Report Detail

Pharma & Healthcare Dynamics in Post-pandemic Global Influenzavirus B Infection Drug Industry: Supply and Demand, Markets and Prices 2021-2027

  • RnM4308683
  • |
  • 13 April, 2021
  • |
  • Global
  • |
  • 181 Pages
  • |
  • GRD Survey
  • |
  • Pharma & Healthcare

Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Influenzavirus B Infection Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Influenzavirus B Infection Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

Segmented by Category
APP-309
CF-403
GC-3106A
KIN-1400
Others

Segmented by End User/Segment
Clinic
Hospital
Others

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
Vectura Group Plc
Vaxart Inc
TSRL Inc
SK Chemicals Co Ltd
Shionogi & Co Ltd
Sanofi
Sanofi Pasteur SA
Romark Laboratories LC
Park Active Molecules
Novavax Inc
Mucosis BV
MedImmune LLC
Medicago Inc
Kineta Inc
Inovio Pharmaceuticals Inc
Green Cross Corp
GlaxoSmithKline Plc
Fujifilm Holdings Corporation
Daiichi Sankyo Company Ltd
ContraFect Corp
Cadila Healthcare Ltd
BioCryst Pharmaceuticals Inc
Aphios Corp
Amarillo Biosciences Inc
Altravax Inc
Adimmune Corp
AbbVie Inc


Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Influenzavirus B Infection Drug Market Status and Forecast (2016-2027)
      • 1.3.2 Global Influenzavirus B Infection Drug Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Influenzavirus B Infection Drug Supply by Company

    • 2.1 Global Influenzavirus B Infection Drug Sales Volume by Company
    • 2.2 Global Influenzavirus B Infection Drug Sales Value by Company
    • 2.3 Global Influenzavirus B Infection Drug Price by Company
    • 2.4 Influenzavirus B Infection Drug Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Influenzavirus B Infection Drug Market Status by Category

    • 3.1 Influenzavirus B Infection Drug Category Introduction
      • 3.1.1 APP-309
      • 3.1.2 CF-403
      • 3.1.3 GC-3106A
      • 3.1.4 KIN-1400
      • 3.1.5 Others
    • 3.2 Global Influenzavirus B Infection Drug Market by Category
      • 3.2.1 Global Influenzavirus B Infection Drug Sales Volume by Category (2016-2021)
      • 3.2.2 Global Influenzavirus B Infection Drug Sales Value by Category (2016-2021)
      • 3.2.3 Global Influenzavirus B Infection Drug Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Influenzavirus B Infection Drug Market Status by End User/Segment

    • 4.1 Influenzavirus B Infection Drug Segment by End User/Segment
      • 4.1.1 Clinic
      • 4.1.2 Hospital
      • 4.1.3 Others
    • 4.2 Global Influenzavirus B Infection Drug Market by End User/Segment
      • 4.2.1 Global Influenzavirus B Infection Drug Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Influenzavirus B Infection Drug Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Influenzavirus B Infection Drug Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Influenzavirus B Infection Drug Market Status by Region

    • 5.1 Global Influenzavirus B Infection Drug Market by Region
      • 5.1.1 Global Influenzavirus B Infection Drug Sales Volume by Region
      • 5.1.2 Global Influenzavirus B Infection Drug Sales Value by Region
    • 5.2 North America Influenzavirus B Infection Drug Market Status
    • 5.3 Europe Influenzavirus B Infection Drug Market Status
    • 5.4 Asia Pacific Influenzavirus B Infection Drug Market Status
    • 5.5 Central & South America Influenzavirus B Infection Drug Market Status
    • 5.6 Middle East & Africa Influenzavirus B Infection Drug Market Status

    6 North America Influenzavirus B Infection Drug Market Status

    • 6.1 North America Influenzavirus B Infection Drug Market by Country
      • 6.1.1 North America Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 6.1.2 North America Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Influenzavirus B Infection Drug Market Status

    • 7.1 Europe Influenzavirus B Infection Drug Market by Country
      • 7.1.1 Europe Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Influenzavirus B Infection Drug Market Status

    • 8.1 Asia Pacific Influenzavirus B Infection Drug Market by Country
      • 8.1.1 Asia Pacific Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Influenzavirus B Infection Drug Market Status

    • 9.1 Central & South America Influenzavirus B Infection Drug Market by Country
      • 9.1.1 Central & South America Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Influenzavirus B Infection Drug Market Status

    • 10.1 Middle East & Africa Influenzavirus B Infection Drug Market by Country
      • 10.1.1 Middle East & Africa Influenzavirus B Infection Drug Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Influenzavirus B Infection Drug Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Influenzavirus B Infection Drug Manufacturing Cost Analysis
    • 11.5 Influenzavirus B Infection Drug Sales Channel and Distributors Analysis
      • 11.5.1 Influenzavirus B Infection Drug Sales Channel
      • 11.5.2 Influenzavirus B Infection Drug Distributors
    • 11.6 Influenzavirus B Infection Drug Downstream Major Buyers

    12 Global Influenzavirus B Infection Drug Market Forecast by Category and by End User/Segment

    • 12.1 Global Influenzavirus B Infection Drug Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Influenzavirus B Infection Drug Forecast by Category
      • 12.2.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by Category
      • 12.2.2 Global Influenzavirus B Infection Drug Sales Value Forecast by Category
      • 12.2.3 Global Influenzavirus B Infection Drug Price Forecast by Category
    • 12.3 Global Influenzavirus B Infection Drug Forecast by End User/Segment
      • 12.3.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Influenzavirus B Infection Drug Sales Value Forecast by End User/Segment
      • 12.3.3 Global Influenzavirus B Infection Drug Price Forecast by End User/Segment

    13 Global Influenzavirus B Infection Drug Market Forecast by Region/Country

    • 13.1 Global Influenzavirus B Infection Drug Market Forecast by Region (2022-2027)
      • 13.1.1 Global Influenzavirus B Infection Drug Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Influenzavirus B Infection Drug Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Vectura Group Plc
      • 14.1.1 Company Information
      • 14.1.2 Influenzavirus B Infection Drug Product Introduction
      • 14.1.3 Vectura Group Plc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Vaxart Inc
      • 14.2.1 Company Information
      • 14.2.2 Influenzavirus B Infection Drug Product Introduction
      • 14.2.3 Vaxart Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 TSRL Inc
      • 14.3.1 Company Information
      • 14.3.2 Influenzavirus B Infection Drug Product Introduction
      • 14.3.3 TSRL Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 SK Chemicals Co Ltd
      • 14.4.1 Company Information
      • 14.4.2 Influenzavirus B Infection Drug Product Introduction
      • 14.4.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Shionogi & Co Ltd
      • 14.5.1 Company Information
      • 14.5.2 Influenzavirus B Infection Drug Product Introduction
      • 14.5.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Sanofi
      • 14.6.1 Company Information
      • 14.6.2 Influenzavirus B Infection Drug Product Introduction
      • 14.6.3 Sanofi Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Sanofi Pasteur SA
      • 14.7.1 Company Information
      • 14.7.2 Influenzavirus B Infection Drug Product Introduction
      • 14.7.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Romark Laboratories LC
      • 14.8.1 Company Information
      • 14.8.2 Influenzavirus B Infection Drug Product Introduction
      • 14.8.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Park Active Molecules
      • 14.9.1 Company Information
      • 14.9.2 Influenzavirus B Infection Drug Product Introduction
      • 14.9.3 Park Active Molecules Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Novavax Inc
      • 14.10.1 Company Information
      • 14.10.2 Influenzavirus B Infection Drug Product Introduction
      • 14.10.3 Novavax Inc Influenzavirus B Infection Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Mucosis BV
    • 14.12 MedImmune LLC
    • 14.13 Medicago Inc
    • 14.14 Kineta Inc
    • 14.15 Inovio Pharmaceuticals Inc
    • 14.16 Green Cross Corp
    • 14.17 GlaxoSmithKline Plc
    • 14.18 Fujifilm Holdings Corporation
    • 14.19 Daiichi Sankyo Company Ltd
    • 14.20 ContraFect Corp
    • 14.21 Cadila Healthcare Ltd
    • 14.22 BioCryst Pharmaceuticals Inc
    • 14.23 Aphios Corp
    • 14.24 Amarillo Biosciences Inc
    • 14.25 Altravax Inc
    • 14.26 Adimmune Corp
    • 14.27 AbbVie Inc

    15 Conclusion

      16 Methodology

      Summary:
      Get latest Market Research Reports on Influenzavirus B Infection Drug. Industry analysis & Market Report on Influenzavirus B Infection Drug is a syndicated market report, published as Dynamics in Post-pandemic Global Influenzavirus B Infection Drug Industry: Supply and Demand, Markets and Prices 2021-2027. It is complete Research Study and Industry Analysis of Influenzavirus B Infection Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,980.00
      $4,470.00
      $5,960.00
      2,360.16
      3,540.24
      4,720.32
      2,759.48
      4,139.22
      5,518.96
      451,023.00
      676,534.50
      902,046.00
      248,532.00
      372,798.00
      497,064.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report